Targeted therapy in oncology
https://doi.org/10.31146/1682-8658-ecg-205-9-222-228
Abstract
The aim of the review is to highlight the principle of action, effectiveness and prospects for the development of targeted therapy in the treatment of patients with malignant neoplasms based on recent clinical studies. Thanks to the active study of tumor biology, specific target molecules have been discovered and it has become possible to target tumor cells with targeted drugs. Today, targeted drugs are used in the treatment of malignant tumors of various organs and continue to demonstrate their effectiveness, improve overall survival and progression-free time, compared with previous standards of treatment.
About the Authors
A. A. Semenkin
Omsk State Medical University
Russian Federation
Russian Federation
V. S. Sapronenko
Omsk State Medical University
Russian Federation
Russian Federation
E. N. Loginova
Omsk State Medical University
Russian Federation
Russian Federation
E. V. Nadey
Omsk State Medical University
Russian Federation
Russian Federation
References
1. Ferlay J., Ervik M., Lam F., et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer; 2020. Available at: https://gco.iarc.fr/today (Accessed: 27 March 2022)
2. Smelov P. A., Nikitina S.YU. (red) Healthcare in Russia. 2021. Moscow. Stat.sb./Rosstat Publ., 2021. (In Russ.) @@Смелов П. А., Никитина С. Ю. (ред) Здравоохранение в России. 2021. - Москва: Стат.сб./Росстат, 2021.
3. Hanahan D., Weinberg R. A. The hallmarks of cancer. Cell. 2000;100(1):57-70. doi:10.1016/s0092-8674(00)81683-9
4. Hanahan D., Weinberg R. A. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013
5. Tyulyandin S. A. Targeted therapy: Twenty years of success and failures. Practical oncology. 2019;4(20):274-288. (In Russ.) doi:10.31917/2004274 @@Тюляндин С. А. Таргетная терапия: двадцать лет успехов и поражений. Практическая онкология. 2019;4(20):274-288. doi:10.31917/2004274
6. Druker B. J., Talpaz M., Resta D. J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. The New England Journal of Medicine. 2001;344(14):1031-1037. doi:10.1056/NEJM200104053441401
7. Lynch T. J., Bell D. W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England Journal of Medicine. 2004;350(21):2129-2139. doi:10.1056/NEJMoa040938
8. Escudier B., Worden F., Kudo M. Sorafenib: key lessons from over 10 years of experience. Expert Review of Anticancer Therapy. 2019;19(2):177-189. doi:10.1080/14737140.2019.1559058
9. Cabanillas M. E., Takahashi S. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Seminars in Oncology. 2019;46(1):57-64. doi:10.1053/j.seminoncol.2018.11.004
10. Cabanillas M. E., Ryder M., Jimenez C. Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. Endocrine Reviews. 2019;40(6):1573-1604. doi:10.1210/er.2019-00007
11. Ramos H. E., Hecht F., Berdelou A., et al. Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer. Endocrine Journal. 2021;71(2):434-442. doi:10.1007/s12020-020-02426-x
12. Kaprin A. D., Ivanov S. A., Sevryukov F. E., et al. Efficacy of external beam radiotherapy and targeted therapy with vandenanib in patients with inoperable and progressive medullary thyroid cancer. Head and neck tumors. 2018;8(3):72-76. (In Russ.) doi:10.17650/2222-1468-2018-8-3-72-76 @@Каприн А. Д., Иванов С. А., Севрюков Ф. Е. и соавт. Эффективность дистанционной лучевой терапии и таргетной терапии вандетанибом нерезектабельного и прогрессирующего медуллярного рака щитовидной железы. Опухоли головы и шеи. 2018;8(3):72-76. doi:10.17650/2222-1468-2018-8-3-72-76
13. Kornblum N., Zhao F., Manola J., et al. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. Journal of Clinical Oncology. 2018;36(16):1556-1563. doi:10.1200/JCO.2017.76.9331
14. André F., Ciruelos E., Rubovszky G., et al. SOLAR-1 Study Group. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. The New England Journal of Medicine. 2019;380(20):1929-1940. doi:10.1056/NEJMoa1813904
15. Genuino A. J., Chaikledkaew U., The D. O., et al. Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis. Expert Review of Clinical Pharmacology. 2019;12(8):815-824. doi:17512433.2019.1637252
16. Cameron D., Piccart-Gebhart M.J., Gelber R. D., et al. Herceptin Adjuvant (HERA) Trial Study Team. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. The Lancet. 2017;389(10075):1195-1205. doi:10.1016/S0140-6736(16)32616-2
17. Mok T., Yang J. J., Lam K. C. Treating patients with EGFR-sensitizing mutations: first line or second line - is there a difference? Journal of Clinical Oncology. 2013;31(8):1081-1088. doi:10.1200/JCO.2012.43.0652
18. Hosomi Y., Morita S., Sugawara S., et al. North-East Japan Study Group. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. Journal of Clinical Oncology. 2020;38(2):115-123. doi:10.1200/JCO.19.01488
19. Remon J., Steuer C. E., Ramalingam S. S., et al. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Annals of Oncology. 2018;29:20-27. doi:10.1093/annonc/mdx704
20. Solomon B. J., Mok T., Kim D. W., et al. PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. The New England Journal of Medicine. 2014;371(23):2167-2177. doi:10.1056/NEJMoa1408440
21. Peters S., Camidge D. R., Shaw A. T., et al. ALEX Trial Investigators. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine. 2017;377(9):829-838. doi:10.1056/NEJMoa1704795
22. Shaw A. T., Riely G. J., Bang Y. J., et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Annals of Oncology. 2019;30(7):1121-1126. doi:10.1093/annonc/mdz131
23. Patel T.H, Cecchini M. Targeted Therapies in Advanced Gastric Cancer. Current Treatment Options in Oncology. 2020;21(9):70. doi:10.1007/s11864-020-00774-4
24. Shitara K., Bang Y. J., Iwasa S., et al. DESTINY-Gastric01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. The New England Journal of Medicine. 2020;382(25):2419-2430. doi:10.1056/NEJMoa2004413
25. Kudo M., Ueshima K., Ikeda M., et al. TACTICS study group. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69(8):1492-1501. doi:10.1136/gutjnl-2019-318934
26. Takeda H., Nishijima N., Nasu A., et al. Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion. Hepatology Research. 2019;49(5):594-599. doi:10.1111/hepr.13294
27. Kudo M., Ueshima K., Chan S., et al. Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study. Cancers. 2019;11(8):1084. doi:10.3390/cancers11081084
28. Bruix J., Qin S., Merle P., et al. RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2017;389(10064):56-66. doi:10.1016/S0140-6736(16)32453-9
29. Van Cutsem E., Tabernero J., Lakomy R., et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. Journal of Clinical Oncology. 2012;30(28):3499-3506. doi:10.1200/JCO.2012.42.8201
30. Piawah S., Venook A. P. Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer. 2019;125(23):4139-4147. doi:10.1002/cncr.32163
31. Biller L. H., Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. Journal of the American Medical Association. 2021;325(7):669-685. doi:10.1001/jama.2021.0106
32. Dhillon S. Regorafenib: A Review in Metastatic Colorectal Cancer. Drugs. 2018;78(11):1133-1144. doi:10.1007/s40265-018-0938-y
33. Chapman P. B., Hauschild A., Robert C., et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England Journal of Medicine. 2011;364(26):2507-2516. doi:10.1056/NEJMoa1103782
34. Robert C., Grob J. J., Stroyakovskiy D., et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. The New England Journal of Medicine. 2019;381(7):626-636. doi:10.1056/NEJMoa1904059
35. Sun J., Carr M. J., Khushalani N. I. Principles of Targeted Therapy for Melanoma. Surgical Clinics of North America. 2020;100(1):175-188. doi:10.1016/j.suc.2019.09.013
Review
For citations:
Semenkin A.A., Sapronenko V.S., Loginova E.N., Nadey E.V. Targeted therapy in oncology. Experimental and Clinical Gastroenterology. 2022;(9):222-228. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-205-9-222-228
Views:
399
Email this article 